Similarly Situated? Anonymous Citizen Petition Takes Aim at Usona’s Psilocybin Application
- The Ask: ‘Consistent’ Standards for Psychedelic NDAs
- The Petition’s Case Against Usona
- Cui Bono? An Unnamed Client
A new Citizen Petition filed with FDA on November 17th (PDF) by D.C. law firm Kleinfeld, Kaplan and Becker (KKB) on behalf of an unnamed client, states that it aims to “assure that psychedelic drug products are uniformly subject to the same rigorous medical and scientific approval framework applicable to other classes of drugs.”
While it nominally concerns all pending psychedelic NDAs, it spends most of its substance critiquing Usona Institute’s psilocybin application.
FDA posted it to a public docket on November 19th. At the time of writing, it had attracted no public comments. The petition has not been reported elsewhere.
The Ask: ‘Consistent’ Standards for Psychedelic NDAs
Specifically, the citizen petition asks the agency to:
- apply the standards for the demonstration of safety and effectiveness set out in statute and FDA’s regulations to all psychedelic NDAs, and,
- apply these standards “in a consistent fashion across all NDAs for psychedelic drug products, subjecting similarly situated applications to the same evidentiary expectations, requests, and standards.”
While the petition lists three pending new drug applications (NDAs), it only goes after one—Usona’s—spending the bulk of the substantive part of the letter critiquing it. And one would assume, given the “similarly situated” language that features in the letter, the petitioner is seeking to draw comparisons between Usona and Compass Pathways’ programs...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks